Denali Therapeutics
DNLI
268 hedge funds and large institutions have $2.82B invested in Denali Therapeutics in 2026 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 104 increasing their positions, 58 reducing their positions, and 30 closing their positions.
80% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 30
79% more repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 58
68% more call options, than puts
Call options by funds: $11.4M | Put options by funds: $6.78M
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
13% more capital invested
Capital invested by funds: $2.5B → $2.82B (+$325M)
7% more funds holding
Funds holding: 250 → 268 (+18)
10.11% less ownership
Funds ownership: 103.06% → 92.95% (-10%)
Top Buyers
Top Sellers
DNLI Hedge Fund Activity: Q1 2026 in Review
268 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q1 2026, worth a combined $2.82B — up 13% from $2.5B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new DNLI positions and 30 closed out — a net gain of 24 holders — while 104 added to existing stakes and 58 trimmed.
The largest buyer was ADAR1 Capital Management, adding an estimated $36.2M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $33.8M sold.
- 268 institutional investors held Denali Therapeutics (DNLI) as of Q1 2026, up from 250 in Q4 2025.
- Funds reported $2.82B of Denali Therapeutics stock for Q1 2026, up 13% quarter-over-quarter.
- 54 funds opened new Denali Therapeutics positions in Q1 2026 and 30 closed out, a net change of +24 holders.
- The largest Denali Therapeutics buyer in Q1 2026 was ADAR1 Capital Management, an estimated $36.2M added.
- The largest Denali Therapeutics seller in Q1 2026 was Point72 Asset Management, an estimated $33.8M sold.
Based on aggregated 13F filings for Q1 2026.